INCY Incyte Corp: רווח למניה ב-12 החודשים האחרונים

Incyte Corporation (INCY) is mitigating risks by expanding its portfolio of medications to combat autoimmune and oncological pathologies. Business growth is driven by the success of Jakafi and the approval of Opzelura. Breakthrough developments in JAK inhibitors are stimulating pipeline growth. The 12-month annual EPS growth trend captures these dynamics, where the value -65.60 describes the company's current yield level.
INCY (Incyte Corp): פילוחים אנליטיים ודוחות לפי אינדיקטורים

This indicator is calculated as the percentage change in the rolling annual net income per share, reflecting the dynamics of capital efficiency. This metric allows an investor to assess the growth rate of business profitability relative to industry averages. For Incyte Corporation (INCY), such dynamics depend directly on the success of costly developments in immuno-oncology and targeted therapy. By analyzing the annual percentage growth of EPS TTM, one can determine how effectively the company's scientific potential is converted into actual profit.